Current treatment status-Undergoing active treatment-No response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Posted by on Jan 12, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...

Read More

Minimal residual disease status after inotuzumab ozogamicin in patients with relapsed/refractory acute lymphoblastic leukemia

Posted by on Jan 7, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if minimal residual disease negativity is useful as a prognostic factor after inotuzumab ozogamicin treatment in patients with relapsed/refractory acute lymphoblastic leukemia.   This study concluded minimal residual negativity with complete remission is associated with a better...

Read More

Managing advanced phase chronic myeloid leukemia

Posted by on Dec 24, 2019 in Leukemia | 0 comments

In a nutshell This study reviewed treatment options for advanced phase chronic myeloid leukemia. This study concluded that managing advanced phase chronic myeloid leukemia remains challenging and treatment options include tyrosine kinase inhibitors, chemotherapy, and transplant.  Some background Chronic myeloid leukemia (CML) can be...

Read More

Searching for patients with relapsed or unresponsive small lymphocytic lymphoma to test an immune cell-stimulating treatment

Posted by on Dec 19, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells.  The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH, the...

Read More

Minimal residual disease response leading to better outcomes for patients with relapsed/refractory acute lymphoblastic leukemia after treatment with blinatumomab

Posted by on Dec 7, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the relationship between minimal residual disease response and outcomes in patients with relapsed/unresponsive B-cell precursor acute lymphoblastic leukemia who were treated with blinatumomab.   This study concluded that achieving minimal residual disease response leads to better outcomes for...

Read More

Evaluating brentuximab vedotin for patients with relapsed or unresponsive Hodgkin lymphoma after SCT

Posted by on Oct 27, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of brentuximab vedotin (Adcetris) to chemotherapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding after a stem cell transplant (SCT). This study concluded that patients treated with brentuximab vedotin had better outcomes compared to patients in the...

Read More

Is tislelizumab safe and effective for patients with relapsed or refractory classical Hodgkin’s lymphoma?

Posted by on Oct 12, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...

Read More

Searching for patients with relapsed/unresponsive non-Hodgkin lymphoma to test an experimental antibody drug

Posted by on Sep 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States. The details Non-Hodgkin lymphoma (NHL) is a...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More